RCUS — Arcus Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $1.75bn
- $938.92m
- $258.00m
- 40
- 16
- 73
- 38
Annual cashflow statement for Arcus Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -123 | 52.8 | -267 | -307 | -283 |
| Depreciation | |||||
| Non-Cash Items | 22.8 | 62.8 | 76 | 64 | 81 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 208 | -376 | 623 | -71 | 22 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 111 | -256 | 438 | -306 | -170 |
| Capital Expenditures | -3.06 | -26.1 | -6 | -24 | -6 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -431 | 22.2 | -407 | 218 | -78 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -434 | -3.87 | -413 | 194 | -84 |
| Financing Cash Flow Items | — | 5 | 10 | 0 | -7 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 439 | 237 | 33 | 33 | 277 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 115 | -22.7 | 58 | -79 | 23 |